Open AccessPatient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer
Author(s) -
Marina Chiara Garassino,
Luis PazAres,
Rina Hui,
Corinne Faivre–Finn,
Alex Spira,
David Planchard,
Mustafa Özgüroğlu,
Davey B. Daniel,
David Vicente,
Shuji Murakami,
Corey J. Langer,
Suresh Senan,
David R. Spigel,
Anna Rydén,
Yiduo Zhang,
Cathy O’Brien,
Phillip A. Dennis,
Scott Antonia
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2020-1102
Subject(s) - durvalumab , medicine , chemoradiotherapy , lung cancer , oncology , post hoc analysis , placebo , population , stage (stratigraphy) , cancer , pathology , immunotherapy , nivolumab , paleontology , alternative medicine , environmental health , biology
Aim: We retrospectively investigated the impact of tumor PD-L1 expression and prior chemoradiotherapy (CRT)-related variables on patient-reported outcomes (PROs) from PACIFIC. Patients & methods: PACIFIC was a Phase III study of durvalumab versus placebo after CRT in patients with unresectable, stage III non-small-cell lung cancer. If available, pre-CRT tumor tissue was tested for PD-L1 tumor-cell expression, scored at prespecified (25%) and post-hoc (1%) cut-offs. PROs were assessed using EORTC QLQ C30/-LC13. Results: Similar to the intent-to-treat (ITT) population, most PROs remained stable over time across PD-L1 and CRT subgroups, with few clinically relevant differences between treatment arms. Time to deterioration was generally similar to the ITT population. Conclusion: Neither PD-L1 expression nor prior CRT-related variables influenced PROs with durvalumab therapy. Clinical trial registration: NCT02125461 (ClinicalTrials.gov)